This article is an erratum on:
Targeted ferroptotic potency of ferrous oxide nanoparticles-diethyldithiocarbamate nanocomplex on the metastatic liver cancer
Frontiers Production OfficeAn Erratum on
Targeted ferroptotic potency of ferrous oxide nanoparticles-diethyldithiocarbamate nanocomplex on the metastatic liver cancer
by Abu-Serie MM (2023). Front. Pharmacol. 13:1089667. doi: 10.3389/fphar.2022.1089667
Due to a production error, there were typing errors made in the article as published.
A correction has been made to the section Abstract:
“Thus, F(II) NPs were used with DE as a nanocomplex (DF(II) NPs), whose anti-LC activity was compared to that of the typical complex, DF(II). In HepG2 cells and a chemically induced metastatic LC animal model, DF(II) NPs outperformed DF(II) in eradicating metastatic LC cells, as evidenced by flow cytometry, histological and immunohistochemical analyses, and α-fetoprotein depletion.”
A correction has been made to the section Introduction:
“Liver cancer (LC) is a lethal malignancy that affects people all over the world. Because of its rapid proliferation, and migration as well as chemoresistance, its progression is difficult to be controlled with existing treatment options, particularly at the advanced stage (metastasis), resulting in a low survival rate (Li et al., 2022; Zhao et al., 2022). Consequently, finding an alternative remedies becomes a current concern. One of the effective therapeutic strategies is inducing ferroptosis, a new non-apoptotic form of regulated cell death which is characterized by iron accumulation-mediated lipid peroxidation propagation (Bekric et al., 2022; Li et al., 2022). It is important to note that unselective induction of ferroptosis can also damage other healthy hepatic cells and tissues (Bekric et al., 2022). Therefore, a nanoformulation of ferroptotic inducers is critical for improving safety by preventing unspecific side effects and enhancing anti-cancer efficacy.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Keywords: metastatic liver cancer, selective ferroptosis, ferrous oxide NPs-diethyldithiocarbamate nanocomplex, blocking antioxidant (anti-ferroptotic) mediators, cancer stem cell genes
Citation: Frontiers Production Office (2023) Erratum: Targeted ferroptotic potency of ferrous oxide nanoparticles-diethyldithiocarba mate nanocomplex on the metastatic liver cancer. Front. Pharmacol. 14:1235710. doi: 10.3389/fphar.2023.1235710
Received: 06 June 2023; Accepted: 06 June 2023;
Published: 13 June 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org